Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724)
- PMID: 1277220
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724)
Similar articles
-
Reduction of ifosfamide toxicity using dose fractionation.Cancer Res. 1976 Aug;36(8):2945-8. Cancer Res. 1976. PMID: 1277203
-
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.Semin Oncol. 1982 Dec;9(4 Suppl 1):66-70. Semin Oncol. 1982. PMID: 7163813 No abstract available.
-
[Ifosfamide in the treatment of small cell carcinoma of the lung].Gan To Kagaku Ryoho. 1983 May;10(5):1293-8. Gan To Kagaku Ryoho. 1983. PMID: 6307164 Japanese.
-
The comparative pharmacology of cyclophosphamide and ifosfamide.Semin Oncol. 1982 Dec;9(4 Suppl 1):2-7. Semin Oncol. 1982. PMID: 6761865 Review. No abstract available.
-
An overview of cyclophosphamide and ifosfamide pharmacology.Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S. Pharmacotherapy. 1997. PMID: 9322882 Review.
Cited by
-
Hemorrhagic Cystitis: Making Rapid and Shrewd Clinical and Surgical Decisions for Improving Patient Outcomes.Res Rep Urol. 2023 Jun 29;15:291-303. doi: 10.2147/RRU.S320684. eCollection 2023. Res Rep Urol. 2023. PMID: 37404838 Free PMC article. Review.
-
Antineoplastic drugs in 1990. A review (Part II).Drugs. 1990 May;39(5):652-73. doi: 10.2165/00003495-199039050-00003. Drugs. 1990. PMID: 2191847 Review. No abstract available.
-
Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin.Pleura Peritoneum. 2019 Nov 6;4(4):20190025. doi: 10.1515/pp-2019-0025. eCollection 2019 Dec 1. Pleura Peritoneum. 2019. PMID: 31799375 Free PMC article.
-
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184. J Cancer Res Clin Oncol. 1988. PMID: 3144554 Free PMC article.
-
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.Cancer Chemother Pharmacol. 1982;9(2):81-4. doi: 10.1007/BF00265383. Cancer Chemother Pharmacol. 1982. PMID: 6816479